Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

ViiV Buys Promising New Mechanisms In HIV From BMS

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline PLC's majority-owned ViiV Healthcare is buying a raft of novel late-stage and early stage HIV assets from Bristol-Myers Squibb Co which it hopes will offer new options for patients who have outlived the utility of other antiretrovirals, thereby expanding ViiV's pipeline and future product sales.